|
Accrued
expenses consisted of the following:
Schedule
of Accrued Expenses
| |
|
June
30,
2020 |
|
|
December
31,
2019 |
|
| |
|
|
|
|
|
|
| Accrued clinical operations and trials costs |
|
$ |
16,901,307 |
|
|
$ |
14,242,669 |
|
| Accrued product development costs |
|
|
5,695,552 |
|
|
|
3,573,231 |
|
| Accrued compensation |
|
|
3,842,249 |
|
|
|
3,673,111 |
|
| Accrued other |
|
|
1,705,036 |
|
|
|
958,928 |
|
| Total |
|
$ |
28,144,144 |
|
|
$ |
22,447,939 |
|
|